-

Circle Pharma to Present at the Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced that Chief Executive Officer David Earp, JD, Ph.D., will present at the following investor conferences:

Circle Pharma Chief Executive Officer David Earp, JD, Ph.D., to present at the 24th Annual Needham Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum.

Share
  • 24th Annual Needham Virtual Healthcare Conference
    April 9, 2025
    11:45 a.m. – 12:25 p.m. ET
  • Stifel 2025 Virtual Targeted Oncology Forum
    April 9, 2025
    1:30 p.m. – 1:55 p.m. ET

About Circle Pharma

South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a Cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial for patients with advanced solid tumors.

To learn more about Circle Pharma, please visit www.circlepharma.com.

Contacts

Media Contact:
Roslyn Patterson
Phone: 650.825.4099
Email: roslyn.patterson@circlepharma.com

Industry:

Circle Pharma

Release Versions
English
Hashtags
#BreastCancer
#LungCancer
#Macrocycles
#SCLC
#TNBC

Contacts

Media Contact:
Roslyn Patterson
Phone: 650.825.4099
Email: roslyn.patterson@circlepharma.com

Social Media Profiles
Circle Pharma on LinkedIn
More News From Circle Pharma

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC). Small-cell lung cancer is a highly aggressive form of lung cancer that accounts for approximately 13–15% of all lung cancer cases1 and is strongly linked to to...

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: “Cyclin A/B-RxL Inhibition as a Novel Therapeutic...

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3 in Chicago. The poster will showcase the design and ongoing progress of its Phase 1 study of CID-078 (NCT06577987), a first-in-class...
Back to Newsroom